# NCT06026657 (NCT06026657)

> Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06026657
- Phase: PHASE1, PHASE2
- Status: RECRUITING
- Sponsor: Margaret Gatti-Mays
- Conditions: Anatomic Stage IV Breast Cancer AJCC v8; HER2-Negative Breast Carcinoma
- Interventions: Biospecimen Collection; Computed Tomography; Gemcitabine; Magnetic Resonance Imaging; Naxitamab; Universal Donor Expanded TGF-beta-imprinted NK Cells
- Enrollment: 42
- Primary outcome: Incidence of adverse events
- Primary outcome: Objective response rate

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- Bluesky threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct06026657